Cadila Pharma's novel three-dose rabies vaccine ThRabis under trial for use in children
India, March 28 -- Ahmedabad-based pharma major Cadila Pharmaceuticals had announced the launch of its novel three-dose recombinant nano-particle based rabies G protein vaccine last year, for adults.
The vaccine ThRabis, prepared by usingVirus-Like Particle technology (VLP), is now undergoing clinical trials for use in children and shall be launched in the market very soon.
During an interaction with BioSpectrum, Dr Arani Chatterjee, Joint President, Cadila Pharma said, "Cadila is the first company in the world to develop a three-dose rabies vaccine in comparison to all the other vaccines which have five doses. This is a big matter of compliance for the patients. Currently, trials are going on for children for this vaccine which is alre...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.